Department of Medical Statistics, School of Public Health & Center for Health Information Research & Sun Yat-sen Global Health Institute, Sun Yat-Sen University, Guangzhou, China.
Department of Immunization Programme Planning, Guangzhou Center for Disease Control and Prevention, Guangzhou, China.
BMJ Glob Health. 2024 Feb 6;9(2):e013444. doi: 10.1136/bmjgh-2023-013444.
China initialised the expanded hepatitis A vaccination programme (EHAP) in 2008. However, the effectiveness of the programme remains unclear. We aimed to comprehensively evaluate the effectiveness of EHAP in the country.
Based on the provincial data on the incidence of hepatitis A (HepA), the population and meteorological variables in China, we developed interrupted time series (ITS) models to estimate the effectiveness of EHAP with the autocorrelation, seasonality and the meteorological confounders being controlled. Results were also stratified by economic zones, age groups and provinces.
We found a 0.9% reduction (RR=0.991, 95% CI: 0.990 to 0.991) in monthly HepA incidence after EHAP, which was 0.3% greater than the reduction rate before EHAP in China. Across the three economic regions, we found a 1.1% reduction in HepA incidence in both central and western regions after EHAP, which were 0.3% and 1.2% greater than the reduction rates before EHAP, respectively. We found a decreased reduction rate for the eastern region. In addition, we found generally increased reduction rate after EHAP for age groups of 0-4, 5-14 and 15-24 years. However, we found decreased reduction rate among the 25-64 and ≥65 years groups. We found a slight increased rate after EHAP in Shanxi Province but not elsewhere.
Our finding provides comprehensive evidence on the effectiveness of EHAP in China, particularly in the central and western regions, and among the population aged 0-24 years old. This study has important implications for the adjustment of vaccination strategies for other regions and populations.
中国于 2008 年启动了扩大甲型肝炎疫苗接种计划(EHAP)。然而,该计划的效果仍不清楚。我们旨在全面评估该计划在中国的效果。
根据中国各省甲型肝炎(HepA)发病率、人口和气象变量数据,我们开发了中断时间序列(ITS)模型,以控制自相关、季节性和气象混杂因素,估计 EHAP 的效果。结果还按经济区、年龄组和省份进行分层。
我们发现 EHAP 后每月 HepA 发病率降低了 0.9%(RR=0.991,95%CI:0.990 至 0.991),比 EHAP 前在中国的降低率高出 0.3%。在三个经济区域中,EHAP 后中部和西部地区 HepA 发病率降低了 1.1%,分别比 EHAP 前高出 0.3%和 1.2%。我们发现东部地区的降低率下降。此外,我们发现 EHAP 后 0-4、5-14 和 15-24 岁年龄组的降低率普遍增加。然而,我们发现 25-64 岁和≥65 岁组的降低率下降。我们发现山西省在 EHAP 后略有增加,但其他省份没有。
我们的发现为 EHAP 在我国,特别是在中部和西部地区以及 0-24 岁人群中的效果提供了全面的证据。本研究对调整其他地区和人群的疫苗接种策略具有重要意义。